Date: February 11, 2025



To, **The Manager**, **BSE Limited Address:** Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400001.

Scrip Code: 540654

Subject: Outcome of Board meeting of the Company held today i.e., Tuesday, February 11, 2025.

<u>Reference: Regulation 30 read with Regulation 33 of the SEBI (Listing Obligations and Disclosures</u> <u>Requirements), 2015 ['Listing Regulations']</u>

Dear Sir/Madam,

This is to inform you that pursuant to Regulation 30 read with Regulation 33 of the Listing Regulations, the Board at its meeting held today i.e., Tuesday, February 11, 2025, through video Conferencing, inter alia, considered and approved the following:

1) Considered and approved the Un-Audited Standalone and Consolidated Financial results along with the Limited Review Report for the quarter and nine months ended December 31, 2024.

These intimations are being given pursuant to provisions of Regulation 30 and Schedule III Part A of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015. Details as per SEBI Master Circular bearing no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are attached as Annexures to this intimation.

The Board Meeting commenced at 04.00 P.M. and concluded at 08.15 P.M.

Kindly take the same on your records.

FOR GLOBALSPACE TECHNOLOGIES LIMITED

Krishna Murari Singh Managing Director DIN: 03160366 Place: Office No. 605, 6th Floor, Rupa Solitaire Building, Millennium Business Park, Mahape, Navi Mumbai 400710.

GLOBALSPACE TECHNOLOGIES LIMITED

Independent Auditor's Limited Review Report on Standalone Unaudited Quarterly Financial Results and year to date results of the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

To, The Board of Directors, Globalspace Technologies Limited

1. We have reviewed the unaudited financial results of GlobalSpace Technologies Limited (the 'Company') for the nine month ended and quarter ended December 31, 2024 (the 'Statement') attached herewith being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016 which has been initialed by us for identification purposes.

2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 Interim Financial Reporting (Ind As 34) prescribed under section 133 of the Companies Act 2013 and Rule 3 of Companies (Indian Accounting Standards) Rules 2015 read with SEBI Circular No.CIR/CFD/FAC/621 2016 dated July 5, 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Accounting Standards and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33

Of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2025 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement, except for the following:

(a.) The inventory register maintained is not updated with details for quantity inwards and quantity outwards, movement of the inventory.

(b.) Equity Commitment towards M/s Miljon Medi App LLP of Rs. 1,144.33 lakhs is pending for share allotment in the books as on 31.12.2024.

BANSILAL SHAH & CO. CHARTERED ACCOUNTANTS

For Bansilal Shah & Co. Chartered Accountants FRN No: 000384W

Dhruv Shah Partner Membership Number 223609 Place: Mumbai Date: 11th February 2025 UDIN: 25223609BMIBKH9784





1027, Hubtown Solaris, N.S. Phadke Marg, Near Teli Gali Signal, Andheri-East, Mumbai-400069, Phone No. 022-67410769, Email: <u>mumbai.blsc@gmail.com</u>, <u>sahil.kothari1@gmail.com</u>



GlobalSpace Technologies Limited Address: 605, Rupa Solitaire Building, Millenium Business Park, Navi Mumbai, Thane - 400710 CIN: L64201MH2010PLC211219

Tel No : 022-49452015, Email id:- cs@globalspace.in, website:- www.globalspace.in

Rs in lacs

Extract of Un-Audited Standalone Financial Results for the Quarter ended and nine month ended December 31, 2024

| Sr. No. | Particulars | Standalone | | | | | | |
|---------|---|---------------|--------------|--------------|-------------------|--------------|------------|--|
| | | Quarter Ended | | | Nine Months ended | | Year Ended | |
| | 1 | - | | 31-Dec-23 | 31-Dec-24 | 31-Dec-23 | 31-Mar-24 | |
| | | (Un-Audited) | (Un-Audited) | (Un-Audited) | (Un-Audited) | (Un-Audited) | (Audited) | |
| 1 | INCOME | | | | | | | |
| a. | Revenue from operation | 907.51 | 814.60 | 781.05 | 2,414.86 | 2,434.88 | 2,904.80 | |
| b. | Other Income | -0.00 | 0.48 | 11.37 | 0.48 | 17.01 | 12.40 | |
| | Total Income | 907.51 | 815.08 | 792.42 | 2,415.34 | 2,451.89 | 2,917.20 | |
| 2 | Expenses | | | | | | | |
| | Cost of materials Consumed | 619.72 | 646.35 | 526.67 | 1,823.76 | 1,551.48 | 1,834.07 | |
| | Changes in Inventory of Stock in trade | 26.45 | 0.30 | 6.78 | 26.75 | 38.07 | 38.07 | |
| | Employee Benefits Expenses | 15.67 | 14.75 | 32.19 | 57.03 | 100.40 | 109.23 | |
| | Depreciation and Amortisation Expenses | 49.13 | 52.22 | 81.06 | 157.44 | 232.12 | 311.34 | |
| | Finance Cost | 32.01 | 25.13 | 44.18 | 88.04 | 144.24 | 175.63 | |
| | Other Expenses | 102.63 | 47.01 | 82.31 | 221.05 | 323.43 | 444.44 | |
| | Total Expenses | 845.60 | 785.76 | 773.18 | 2,374.06 | 2,389.74 | 2,912.77 | |
| 3 | Profit/Loss Before Exceptional Items and tax(1-2) | 61.91 | 29.32 | 19.24 | 41.28 | 62.15 | 4.43 | |
| | Exceptional Items | - | | | -275.65 | | 385.66 | |
| 4 | Profit/(Loss)before tax | 61.91 | 29.32 | 19.24 | -234.37 | 62.15 | -381.23 | |
| | Tax Expense | | | | | | | |
| | Current Tax | - | | 4.47 | | 16.14 | | |
| | Deferred Tax | 0.00 | 20.96 | -0.09 | -41.94 | -4.83 | -28.13 | |
| | Total Tax Expenses | 0.00 | 20.96 | 4.37 | -41.94 | 11.31 | -28.13 | |
| 6 | Net Profit/(Loss) after tax(4-5) | 61.90 | 8.36 | 14.87 | -192.44 | 50.84 | -353.11 | |
| 7 | Other Comprehensive Income | | | | | | | |
| | Items that will not be reclassified into Profit or Loss | 0.50 | -0.50 | - | - | - | 0.52 | |
| | Total Comprehensive Income | 0.50 | - | - | - | - | 0.52 | |
| 8 | Total Comprehensive Income for the year (after tax) (6+7) | 62.40 | 7.86 | 14.87 | -192.44 | 50.84 | -352.59 | |
| 11 | Paid-up Equity Share Capital (Face Value of Re. 10 /- each) | 3,436.98 | 3,436.98 | 3,436.98 | 3,436.98 | 3,436.98 | 3,436.98 | |
| 12 | Other Equity | 2,011.42 | 1,949.01 | 6,378.16 | 2,011.42 | 6,378.16 | 2,203.86 | |
| 13 | Earnings per Equity Share (of Rs. 10/- each) | | | | | | | |
| | Basic | 0.59 | 0.07 | 0.14 | -1.82 | 0.48 | -1.84 | |
| | Diluted | 0.59 | 0.07 | 0.14 | -1.82 | 0.48 | -1.84 | |

Notes:

1 The above results were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 11th February 2025

2 The Statutory auditors have conducted the Quarterly and nine month ended Review of the financial statements and have expressed an un qualified audit opinion.

- 3 The Group operates in a single segment. Hence, segment reporting is not applicable.
- 5 Previous period figures have been re-grouped / re-classified wherever necessary.

For Bansilal Shah & Co Chartered Accountants FRN No : 000384W

Firm Registration Number:111017W

CA Dhruv Shah Partner Membership No : 223609 UDIN: 25223609BMIBKH9784 Place: Mumbai 11.02.2025



For Globalspace Technologies Limited LM OVAS

Krishna Murari Singh Chairman and Managing Director DIN : 03160366

Place: Navi Mumbai Mumbai : 11.02.2025

BANSILAL SHAH & CO.

CHARTERED ACCOUNTANTS

Independent Auditor's Limited Review Report on Consolidated Unaudited nine month and Quarterly ended Financial Results and year to date results of the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

To, The Board of Directors, Globalspace Technologies Limited

1. We have reviewed the unaudited financial results of GlobalSpace Technologies Limited (the 'Company') for the nine month and quarter ended December 31, 2024 (the 'Statement') attached herewith being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016 which has been initialed by us for identification purposes.

2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 Interim Financial Reporting (Ind As 34) prescribed under section 133 of the Companies Act 2013 and Rule 3 of Companies (Indian Accounting Standards) Rules 2015 read with SEBI Circular No.CIR/CFD/FAC/621 2016 dated July 5, 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Accounting Standards and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33

Of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2025 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement, except for the following:

- The controlling stake of 51% in the subsidiary company Innopharma Healthcare Private Limited has been acquired on 17th June 2024 and hence no comparative quarter/ half year/ year except for the once prepared after acquisition i.e. quarter needed 30th June 2024, quarter and half year ended 30th September 2024 and quarter and nine month ended 31st December 2024.
- The accounts of the subsidiary have been not been reviewed by us and we have relied upon the financial statement as drafted by the auditor of the subsidiary.

For Bansilal Shah & Co. Chartered Accountants FRN No: 000384W

Dhruv Shah Partner Membership Number 223609 Place: Mumbai Date: 9th December 2024 UDIN: 25223609BMIBKI7266





GlobalSpace Technologies Limited Address: 605, Rupa Solitaire Building, Millenium Business Park, Navi Mumbai, Thane - 400710 CIN: L64201MH2010PLC211219 Tel No : 022-49452015, Email id:- cs@globalspace.in, website:- www.globalspace.in

Extract of Un-Audited Standalone and Consolidated Financial Results for the guarter ended December 31, 2024

| Sr. No. | Particulars | Consolidated | | | | | |
|---------|--|--------------|-------------------|--------------|--|--|--|
| | | Quart | Nine Months ended | | | | |
| | | 31-Dec-24 | 30-Sep-24 | 31-Dec-24 | | | |
| | | (Un-Audited) | (Un-Audited) | (Un-Audited) | | | |
| 1 | INCOME | | | | | | |
| a. | Revenue from operation | 1,268.98 | 1,157.36 | 3,429.45 | | | |
| b. | Other Income | 1.76 | 2.06 | 3.82 | | | |
| | Total Income | 1,270.74 | 1,159.42 | 3,433.27 | | | |
| 2 | Expenses | | | - | | | |
| | Cost of materials Consumed | 619.72 | 646.35 | 1,823.76 | | | |
| | Changes in Inventory of Stock in trade | 26.45 | - | 26.75 | | | |
| | Employee Benefits Expenses | 291.71 | 281.88 | 842.40 | | | |
| | Depreciation and Amortisation Expenses | 49.56 | 52.99 | 158.64 | | | |
| | Finance Cost | 32.01 | 25.13 | 88.04 | | | |
| | Other Expenses | 183.49 | 125.33 | 443.13 | | | |
| | Total Expenses | 1,202.93 | 1,131.68 | 3,382.71 | | | |
| 3 | Profit/Loss Before Exceptional Items and tax(1- 2) | 67.81 | 27.74 | 50.56 | | | |
| | Exceptional Items | | | (275.65) | | | |
| | Finance Cost | | | | | | |
| 4 | Profit/(Loss)before tax | 67.81 | 27.74 | (225.09) | | | |
| | Tax Expense | | | - | | | |
| | Current Tax | 0.41 | 0.81 | 1.22 | | | |
| | Deferred Tax | 0.02 | 20.99 | (41.88) | | | |
| | Total Tax Expenses | 0.42 | 21.80 | (40.67) | | | |
| 6 | Net Profit/(Loss) after tax(4-5) | 67.38 | 5.94 | (184.43) | | | |
| 7 | Other Comprehensive Income | - | | | | | |
| | Items that will not be reclassified into Profit or Loss | 0.50 | (0.50) | | | | |
| | | 0.50 | (0.50) | | | | |
| | Total Comprehensive Income Total Comprehensive Income for the year (after | | (0.50) | - | | | |
| 8 | tax) (5+6) | 67.88 | 5.44 | (184.43) | | | |
| 10 | Less: Share of Non Controlling Interest | - | 1.24 | (10.1.0) | | | |
| | Total Comprehensive Income for the year (after | | | | | | |
| 11 | tax) for controlling interest (5+6) | 67.88 | 4.20 | (184.43) | | | |
| 12 | Paid-up Equity Share Capital (Face Value of Re. | | | | | | |
| | 10 /- each) | 3,436.98 | 3,436.98 | 3,436.98 | | | |
| 13 | Other Equity | 2,019.72 | 1,951.84 | 2,019.43 | | | |
| 14 | Earnings per Equity Share (of Rs. 10/- each) | | | | | | |
| | Basic | 0.20 | 0.02 | (0.54) | | | |
| | Diluted | 0.20 | 0.02 | (0.54) | | | |

Notes: 1

The above results were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 11th February 2025

2 The Statutory auditors have conducted the Review of the financial statements and have expressed an un qualified audit opinion.

3 The Group operates in a single segment. Hence, segment reporting is not applicable.

4 Previous period figures have been re-grouped / re-classified wherever necessary.

5 The controlling stake of 51% in the subsidiary company Innopharma Healthcare Private Limited has been acquired on 17th June 2024 and hence no comparative quarter/ half year/ year except for the once prepared after acquisition i.e. quarter needed 30th June 2024and 30th September 2024.

6 The Company has the following subsidiary/associate/joint venture company(ies), as on December 31, 2024, Innopharma Healthcare Private Limited: 51% Investment in Miljon Mediapp LLP : 95%

7 Previous period figures have been re-grouped / re-classified wherever necessary.

ed Acc

For Bansilal Shah & Co Chartered Accountants FRN No : 000384W

CA Dhruv Shah Partner Membership No : 223609 UDIN: 25223609BMIBKI7266 Place: Mumbai Date : 11.02.2025 For Globalspace Technologies Limited

TOV.

Krishna Murari Singh Chairman and Managing Director DIN : 03160366

Place: Navi Mumbai Date : 11.02.2025